Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Scalar Product (Dot Product)01:11

Scalar Product (Dot Product)

27.8K
The scalar multiplication of two vectors is known as the scalar or dot product. As the name indicates, the scalar product of two vectors results in a number, that is, a scalar quantity. Scalar products are used to define work and energy relations. For example, the work that a force (a vector) performs on an object while causing its displacement (a vector) is defined as a scalar product of the force vector with the displacement vector.
The scalar product of two vectors is obtained by multiplying...
27.8K
Vector Product (Cross Product)01:17

Vector Product (Cross Product)

28.1K
Vector multiplication of two vectors yields a vector product, with the magnitude equal to the product of the individual vectors multiplied by the sine of the angle between both the vectors and the direction perpendicular to both the individual vectors. As there are always two directions perpendicular to a given plane, one on each side, the direction of the vector product is governed by the right-hand thumb rule.
Consider the cross product of two vectors. Imagine rotating the first vector about...
28.1K
Primary Production01:06

Primary Production

25.4K
The total amount of energy acquired by primary producers in an ecosystem is called gross primary production (GPP). However, of this energy, producers use some for metabolic processes, and some is lost as heat, decreasing the amount of energy available to the next trophic level. The remaining usable amount of energy is called the net primary productivity (NPP). In terrestrial ecosystems, NPP is driven by climate, while light penetration and nutrient availability drive NPP in aquatic ecosystems.
25.4K
Production Efficiency01:01

Production Efficiency

18.4K
Net production efficiency (NPE) is the efficiency at which organisms assimilate energy into biomass for the next trophic level. Due to low metabolic rates and less energy spent on thermoregulatory processes, the NPE of ectotherms (cold-blooded animals) is 10 times higher than endotherms (warm-blooded animals).
18.4K
The Dot Product01:26

The Dot Product

265
Measuring how one directional quantity affects another along a specific path involves comparing their orientation and strength. When two such quantities are represented using direction and amount, a numerical result is computed to show how much one acts along the path of the other. This result comes from a rule combining both inputs' horizontal and vertical parts and adding the results.This calculation gives a single value that grows larger when both inputs point in similar directions and...
265
Dot Product01:29

Dot Product

992
The dot product is an essential concept in mathematics and physics.
In engineering, the dot product of any two vectors is the product of the magnitudes of the vectors and the cosine of the angle between them. It is denoted by a dot symbol between the two vectors.
Consider a vehicle pulling an object along the ground using a rope. If the rope makes an angle with the horizontal axis, the work done can be calculated using the dot product of the force applied and the object's displacement.
The dot...
992

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental oxygen affects ex vivo growth and proliferation of mesenchymal progenitors by modulating mitogen-activated protein kinase and mammalian target of rapamycin signaling.

Cytotherapy·2022
Same author

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.

Blood·2022
Same author

The National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy.

Clinical and translational science·2021
Same author

A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.

European journal of heart failure·2021
Same author

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2021
Same author

Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial.

JACC. CardioOncology·2021
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Feb 8, 2026

Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

14.6K

GMP CAR-T cell production.

Adrian P Gee1

  • 1cGMP Facilities, Center for Cell & Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.

Best Practice & Research. Clinical Haematology
|June 19, 2018
PubMed
Summary
This summary is machine-generated.

Academic institutions are exploring in-house manufacturing of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapies. This review covers essential considerations for successful CAR-T cell production, including infrastructure, regulations, and costs.

Keywords:
CAR-T cellsGood manufacturing practicesManufacturing

More Related Videos

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

5.1K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

899

Related Experiment Videos

Last Updated: Feb 8, 2026

Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

14.6K
Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

5.1K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

899

Area of Science:

  • Immunotherapy
  • Cellular Therapy
  • Oncology

Background:

  • Clinical success of CD19-directed CAR-T cells is driving interest in academic manufacturing.
  • CAR-T cell therapy represents a significant advancement in cancer treatment.

Purpose of the Study:

  • To review the key considerations for academic institutions aiming to establish in-house CAR-T cell manufacturing.
  • To provide a comprehensive overview of the challenges and requirements for producing CAR-T therapies.

Main Methods:

  • Review of manufacturing infrastructure requirements.
  • Analysis of the regulatory landscape for cellular therapies.
  • Examination of practical production aspects.
  • Cost analysis of in-house CAR-T production.

Main Results:

  • Establishing in-house CAR-T manufacturing requires significant investment in infrastructure.
  • Navigating the complex regulatory environment is crucial for compliance.
  • Efficient production processes and cost management are vital for feasibility.

Conclusions:

  • Academic institutions must address infrastructure, regulatory, and practical challenges to achieve successful in-house CAR-T manufacturing.
  • Careful planning regarding costs and production is essential for the viability of academic CAR-T programs.